Lyophilized preparations of melphalan flufenamide
The present invention is directed to lyophilized pharmaceutical preparations comprising melphalan flufenamide, or pharmaceutically acceptable salts thereof, and sucrose. Further independent claims are directed to methods for their preparation, compositions comprising the lyophilized pharmaceutical preparations and their use in the treatment of cancer.
1. A lyophilized pharmaceutical preparation which is directly soluble in a physiologically acceptable aqueous solution, said pharmaceutical preparation comprising melphalan flufenamide or a pharmaceutically acceptable salt thereof and sucrose in a weight ratio (w/w) of from about 1:25 to about 1:75.
2. A lyophilized pharmaceutical preparation according to claim 1 , wherein the weight ratio (w/w) between said melphalan flufenamide or pharmaceutically acceptable salt thereof and sucrose is about 1:50.
3. A lyophilized pharmaceutical preparation according to claim 1 , comprising about 25 mg melphalan flufenamide hydrochloride (J1) and about 1.25 g sucrose.
4. A lyophilized pharmaceutical preparation according to claim 1 , comprising about 50 mg melphalan flufenamide hydrochloride (J1) and about 2.5 g sucrose.
5. A lyophilized pharmaceutical preparation according to claim 1 , comprising about 15 mg melphalan flufenamide hydrochloride (J1) and about 0.75 g sucrose.
6. A lyophilized pharmaceutical preparation to claim 1 , comprising about 20 mg melphalan flufenamide hydrochloride (J1) and about 1.0 g sucrose.
7. A lyophilized pharmaceutical preparation according to claim 1 , comprising about 40 mg melphalan flufenamide hydrochloride (J1) and about 2.0 g sucrose.
8. A lyophilized pharmaceutical preparation according to claim 1 , comprising about 55 mg melphalan flufenamide hydrochloride (J1) and about 2.75 g sucrose.
9. A lyophilized pharmaceutical preparation according to claim 1 , comprising about 200 mg melphalan flufenamide hydrochloride (J1) or higher.
10. A lyophilized pharmaceutical preparation according to claim 1 , which is free, or substantially free from organic solvents.
11. A lyophilized pharmaceutical preparation according to claim any one of claim 1 , 2 or 10 , wherein the melphalan flufenamide or pharmaceutically acceptable salt thereof is melphalan flufenamide hydrochloride (J1).
12. A composition made by directly reconstituting the lyophilized pharmaceutical preparation according to claim 11 in a physiologically acceptable solution.
13. The composition according to claim 12 , wherein said physiologically acceptable solution is a glucose solution.
14. The composition according to claim 13 , wherein the amount of glucose is about 4.5-5.5% by weight of the physiologically acceptable solution.
15. A kit of parts combination comprising
(i) a lyophilized pharmaceutical preparation according to claim 1 ; and
(ii) a physiologically acceptable solution.
16. A kit of parts combination according to claim 15 , wherein the physiologically acceptable solution is a glucose solution.
17. A kit of parts combination according to claim 16 , wherein the amount of glucose is about 4.5-5.5% by weight of the physiologically acceptable solution.
18. The lyophilized pharmaceutical composition of claim 11 , in which sucrose is the sole excipient.
19. The lyophilized pharmaceutical composition of claim 11 , which consists essentially of J1 and sucrose.
20. The lyophilized pharmaceutical composition of claim 11 , which is obtained by lyophilizing a solution comprising J1, sucrose, tert-butanol and water.
21. The lyophilized pharmaceutical composition of claim 1 , wherein the melphalan flufenamide or a pharmaceutically acceptable salt thereof is a pharmaceutically acceptable salt thereof.
22. The lyophilized pharmaceutical composition of claim 2 , wherein the melphalan flufenamide or a pharmaceutically acceptable salt thereof is a pharmaceutically acceptable salt thereof.